ASCO17: AstraZeneca pumps up expectations on near-term cancer drug wins, looking to shed a rep for failure
CHICAGO — AstraZeneca’s R&D team arrived at ASCO on a critical mission.
With its leading PARP inhibitor outscoring chemo in treating breast cancer, making the spotlight round on Sunday, AstraZeneca was able to offer some fresh, solid evidence of its continuing progress on the all-important cancer front. And with several key catalysts lined up over the summer, execs wanted to send a clear message that this cancer drug roll they’re on is just beginning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.